Multiple analytes on one instrument
Multiple sample types
All-in-one test cartridge
Automatic self-check system
No additional calibration necessary
Throughput: 480 tests/hour 580 tests/hour with ISE
Test items on board: 36 items + ISE 3 items
Reaction volume: 120– 300 micro-liter
Patient samples on board: 72 patient samples, 30 STAT samples
Reaction volume: 140– 300 micro-liter
Test items on board: 24 items + ISE 3 items / 36 items + ISE 3 items
Patient samples on board: 30 patient samples
Throughput: 270 tests/hour 450 tests/hour with ISE
R1: 140 ～ 300μl (1μl step）
R2: 20 ～ 260μl (1μl step）
News and Announcements
Breast cancer is predicted to be the second leading cause of cancer deaths in the USA women. Approximately 232,000 cases of invasive breast cancer and 60,000 cases of ductal carcinoma in situ (DCIS) are diagnosed and 40,000 deaths occur annually. A multi-protein biomarker blood test that is able to detect breast cancer can help inform better decision-making after abnormal mammogram or other breast imaging results and potentially reduce use of biopsy by up to 67%. If diagnosed early in a localized state, five-year survival rates are greater than 98%.
Medical scientists working with a privately held molecular diagnostics company carried out two prospective, randomized, multi-center and blinded clinical trials, in more than 1,350 patients, ages 25-75. It is the first prospective study of a proteomic assay composed of serum protein biomarkers and tumor-associated autoantibodies being used to detect breast cancer in women with abnormal imaging results. Serum was evaluated for 11 serum protein biomarkers and 33 tumor-associated autoantibodies. The team used the Videssa Breast (Provista Diagnostics, Inc, New York, NY, USA), which is the first blood-based proteomic test of its kind to provide early and accurate detection of breast cancer. The overall performance of Videssa Breast in women with a breast cancer prevalence of 5.87% resulted in a sensitivity of 87.5%, specificity of 83.8%, positive predictive value (PPV) of 25.2% and a negative predictive value (NPV) of 99.1%.
Read More Here
Primary infections of Toxoplasma and rubella in pregnant women may result in vertical transmission of the pathogens, which can cause congenital disease that significantly affects fetal development.
Since clinical manifestations of toxoplasmosis and rubella can be absent or nonspecific, serological screening for both diseases in pregnant women is routinely performed worldwide. Currently, tests such as enzyme immunoassay (EIA), enzyme-linked fluorescent assay (ELFA), chemiluminescent microparticle immunoassay, and electrochemiluminescence immunoassay are widely applied in clinical laboratories to diagnose toxoplasmosis. Scientists at the Carlos Chagas Institute (Curitiba, Brazil) developed a multiplex assay for simultaneous detection of immunoglobulin G (IgG) antibodies produced during toxoplasmosis and rubella infection. They used a quality control panel of contains 92 anti-Toxoplasma gondii IgG-positive serum samples and 30 negative serum samples. The samples were tested for T. gondii IgG by a Vidas ELFA assay. There is no clinical data associated with these samples. To develop assays for the detection of rubella, 23 serum or plasma samples classified as positive for anti- Rubella virus IgG antibodies and two samples negative for anti-R. virus IgG antibodies were used.
The multiplex assay, based on xMap technology to simultaneously diagnose toxoplasmosis and rubella was designed with the best-performing antigens in singleplex and multiplex assays, which included CTOXH, T. gondii lysate, TOX8131, E-1, and E-2. The multiplex assay showed 100% sensitivity and specificity for anti-T. gondii IgG detection and 95.6% sensitivity and 100% specificity for anti-R. virus IgG detection. Fluorescence and median fluorescence intensity (MFI) were determined using a Luminex 200 reader.Read More Here
Heart failure can often be managed with medications and lifestyle changes, but its progression needs to be monitored closely to adjust treatment and prevent emergency room visits. Now scientists have developed a simple paper test strip that could potentially allow patients to monitor themselves for the first time. Antigens ST2 and BNP are good indicators of heart failure and its progression. Currently, analyzing the levels of these biomarkers requires trained personnel and sophisticated lab equipment. The research team, lead by study corresponding authors Prof. Feng Xu and Prof. Min Lin of Xi’an Jiaotong University (Xi’an, Shaanxi, China), devised a simple assay to enable doctors and patients to carry out the same analysis at the office or at home.
The team developed a fluorescent lateral-flow strip platform that requires a blood sample of only 10 microliters. A blue dot glows on the strip if ST2 is present in the sample, and a green dot glows if it contains BNP. The colors’ intensities increase with concentration, which indicates that a person’s heart failure is likely becoming worse. A smartphone app can analyze the readout and send the results to the patient’s doctor, who can adjust treatment accordingly. Testing 38 serum samples from people with heart failure showed that the paper-based test closely matched conventional techniques.More Read Here
A team of investigators has discovered a gene, named fosA7, which confers a high level of resistance to the important broad-spectrum antibiotic fosfomycin. The researchers found fosA7 in isolates of the pathogen Salmonella enterica from broiler chickens. Fosfomycin has been a safe and effective agent for eliminating infections caused by multidrug-resistant bacteria. The product of fosA7 is the enzyme glutathione-S-transferase, which inactivates fosfomycin by binding to it and rupturing a molecular ring its structure. The “7” in fosA7 indicates that this is the seventh antibiotic resistant fosA gene that has been discovered.
“Vigilant monitoring for the spread of fosfomycin resistance in bacteria, isolated from humans and animals, is needed,” said corresponding author Moussa S. Diarra, PhD, research scientist at from Agriculture and Agri-Food Canada (AAFC; Guelph, Ontario, Canada). Currently, there is only limited fosfomycin resistance among Salmonella species. But the powerful resistance the fosA7 gene confers is worrisome, said Dr. Diarra. It could spread via horizontal gene transfer among different Salmonella serovar strains as well as other to bacterial pathogens, due to increased use of fosfomycin in both clinical and veterinary settings. With that in mind, the researchers tested the strength of the resistance that fosA7 could confer on the closely related Salmonella enterica serovar Enteritidis by inserting the gene into the chromosome of non-antibiotic-resistant S. Enteriditis. Their worries were confirmed: the gene boosted the minimum concentration of fosfomycin required to inhibit microbe reproduction by more than 256-fold.
More Read Here
Subscribe to our newsletter to receive news, updates, and another stuff by email.